ITCH RELIEF

NEMLUVIO delivers fast and lasting itch relief¹

Itch relief as soon as

48

hours

(P=0.0196)*

49% of patients achieved significant itch relief^† at Week 16 vs 16% with placebo (P<0.0001)^2‡

Actor portrayal.

More than 8 out of 10 patients saw itch relief with over a year of treatment¹

83% of NEMLUVIO™ patients achieved continued itch improvement over 68 weeks.

Data from observed cases in OLYMPIA 2 treat-through population, interim analysis of the OLYMPIA LTE. No imputations for missing data. In the full population, 86% of patients (n=152) achieved PP-NRS improvement at Week 52.^1,4

REVIEW STUDY DESIGN

Assessments & Scales

Peak PRURITUS Numerical Rating Scale (PP-NRS)³

Patient-reported outcome designed to measure the worst itch over the previous 24-hour period
Treatment success defined as at least a 4-point improvement from baseline

68%

of patients taking NEMLUVIO were itch‑free or nearly itch‑free with over a year of treatment¹

Itch-free status defined as PP-NRS <2⁵

Data from observed cases in the OLYMPIA 2 NEMLUVIO treat‑through population, Week 52 interim analysis of the OLYMPIA LTE. In the full population, 66% of patients (n=163) achieved PP‑NRS <2 at Week 52.^1,4

Lasting Skin Healing¹

Discover how NEMLUVIO healed most PN nodules for PN patients¹

SEE THE DIFFERENCE

Favorable Safety Profile²

NEMLUVIO offers a favorable safety profile and requires no preliminary lab evaluations or ongoing lab monitoring²

REVIEW SAFETY PROFILE

Sign up now for more information about NEMLUVIO and PN

SIGN UP

Data from post-hoc descriptive analysis of daily PP-NRS improvement for OLYMPIA 2; consistent results seen in OLYMPIA 1.¹

PP-NRS response defined as ≥4-point improvement from baseline.²

Data shown from OLYMPIA 2; in OLYMPIA 1, 56% of patients achieved significant itch relief vs 16% for placebo.¹

LTE=long-term extension; PN=prurigo nodularis; PP-NRS=Peak Pruritus Numerical Rating Scale.

References: 1. Galderma Laboratories, L.P.; data on file. 2. NEMLUVIO (nemolizumab-ilto) injection 30 mg Prescribing Information. Dallas, TX: Galderma Laboratories, L.P.; August 2024. 3. Kwatra SG, Misery L, Clibborn C, Steinhoff M. Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics. Clin Transl Immunology. 2022;11(5):e1390. doi:10.1002/cti2.1390 4. Galderma Laboratories, L.P.; data on file. Clinical Study Report RD.06.SIR.202699; October 2023. 5. Kwatra SG, Yosipovitch G, Legat FJ, et al. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023;389(17):1579-1589. doi:10.1056/NEJMoa2301333

IMPORTANT SAFETY INFORMATION

INDICATION: NEMLUVIO^® (nemolizumab-ilto) is an interleukin-31 receptor antagonist indicated for the treatment of adults with prurigo nodularis.

CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

WARNINGS AND PRECAUTIONS:
Hypersensitivity reactions have been reported with NEMLUVIO use. If clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO.

ADVERSE REACTIONS:
Most common adverse reactions (incidence ≥1%) are headache, dermatitis atopic, eczema, and eczema nummular.

USE IN SPECIFIC POPULATIONS:
Pregnancy: There are no adequate and well-controlled studies on NEMLUVIO in pregnant women. The limited available information on NEMLUVIO use during pregnancy is not sufficient to inform a drug-associated risk of major birth defects or miscarriage in humans. Human IgG antibodies are known to cross the placental barrier; therefore, NEMLUVIO may be transmitted from the mother to the developing fetus.

Lactation: There are no data on the presence or transfer of NEMLUVIO in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. The effects of local gastrointestinal and limited systemic exposure to NEMLUVIO on the breastfed infant are unknown. NEMLUVIO has not been administered to nursing/lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NEMLUVIO and any potential adverse effects on the breastfed child from NEMLUVIO or from the underlying maternal condition.

Please see full Prescribing Information, including Patient Information.